ImmuCell vs Anbio Biotechnology
ICCC and NNNN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ICCC and NNNN compare
ImmuCell grew revenue faster over the last twelve months (19.6% versus 5.6% for Anbio Biotechnology).
Anbio Biotechnology keeps more of each dollar of sales as profit, with a net margin of 74.1% compared with 5.7% at ImmuCell.
ImmuCell scores higher on the StockData Score (12 against 11 for Anbio Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ICCC | NNNN |
|---|---|---|
| Size and price | ||
| Market cap | $97.6M | – |
| Share price | $10.75 | $3.82 |
| Change, 1 year | 75.4% | −83.0% |
| Change, 5 years | 21.6% | – |
| Beta (5Y) | 0.11 | 1.55 |
| Employees | 73 | 27 |
| StockData Score | ||
| Total score | 12 (better) | 11 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 | 5 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 53.8× | – |
| P/S | 2.9× | – |
| P/B | 3.0× | – |
| EV/EBITDA | 14.0× | – |
| P/FCF | 18.1× | – |
| FCF yield | 5.5% | – |
| Fair value | $8.85 | – |
| Margin of safety | −21.5% | – |
| Growth | ||
| Revenue growth (TTM) | 19.6% (better) | 5.6% |
| Revenue growth, 5Y average | 12.5% | – |
| Net income growth (TTM) | −19.1% | 170% (better) |
| EPS growth (TTM) | −23.1% | 163% (better) |
| Profitability | ||
| Gross margin | 40.8% | 87.2% (better) |
| Operating margin | 14.5% | 66.7% (better) |
| Net margin | 5.7% | 74.1% (better) |
| FCF margin | 16.3% | – |
| Return on equity | 6.0% | 27.0% (better) |
| Return on invested capital | 13.8% | 48.7% (better) |
| Financial health | ||
| Debt / equity | 0.24 (better) | 0.00 |
| Net debt / EBITDA | −0.00 | – |
| Interest coverage | 12.2× | – |
| Current ratio | 4.61 | 344.31 (better) |
| Altman Z-score | 5.00 | – |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 14.7% | – |
| Held by insiders | 13.6% | 0.00% |
| Insider net buying, 12 months | $156K | – |
| Short interest, % of float | 0.19% | 0.02% |
Go deeper
- ICCC stock overview
- ICCC income statement
- ICCC valuation and score
- NNNN stock overview
- NNNN income statement
- NNNN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.